{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T11:50:40Z","timestamp":1787313040770,"version":"build-2736575974"},"reference-count":52,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2025,3,2]],"date-time":"2025-03-02T00:00:00Z","timestamp":1740873600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Clinical Apheresis"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Autologous stem cell transplant (ASCT) requires the collection of hematopoietic progenitor cells, commonly by apheresis (HPC\u2010A). These CD34+ cells can be mobilized using Granulocyte Colony Stimulating Factor (G\u2010CSF) only or chemomobilization plus G\u2010CSF. Both methods may additionally include Plerixafor. The emergence of COVID\u201019 led to recommendations for preferential G\u2010CSF only mobilization. To assess the impact of this recommendation on HPC\u2010A harvesting, we analyzed data from the NHS Blood and Transplant Stem Cell Collection Registry for 1342 patients undergoing 2431 HPC\u2010A procedures between 01\/01\/2019 and 31\/12\/2021. We compared G\u2010CSF only, cyclophosphamide plus G\u2010CSF (Cyclo\u2010G) and G\u2010CSF plus alternative chemotherapy (Chemo+G) mobilization. The outcomes collected were pre\u2010apheresis CD34+ count, CD34+ yield per procedure, total CD34+ yield, number of apheresis procedures required to achieve the CD34+ target, mobilization failure, and Plerixafor use (+P). In multiple myeloma (MM), Cyclo\u2010G (+\/\u2212P) mobilization produced significantly higher CD34+ yields than G\u2010CSF only (7.44 vs. 4.75\u2009\u00d7\u200910\n                    <jats:sup>6<\/jats:sup>\n                    \/kg;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.0001). In Hodgkin lymphoma (HL) there was no statistically significant difference between regimes (CD34+ yield 4.53\u2009\u00d7\u200910\n                    <jats:sup>6<\/jats:sup>\n                    \/kg with G\u2010CSF only (+\/\u2212P), 5.52\u2009\u00d7\u200910\n                    <jats:sup>6<\/jats:sup>\n                    \/kg with Cyclo\u2010G (+\/\u2212P), 4.32\u2009\u00d7\u200910\n                    <jats:sup>6<\/jats:sup>\n                    \/kg with Chemo+G (+\/\u2212P)). In Non\u2010Hodgkin lymphoma (NHL), Chemo+G (+\/\u2212P) was the most successful regime (5.98\u2009\u00d7\u200910\n                    <jats:sup>6<\/jats:sup>\n                    \/kg vs. 3.7\u2009\u00d7\u200910\n                    <jats:sup>6<\/jats:sup>\n                    \/kg with G\u2010CSF only (+\/\u2212P) vs. 3.69\u2009\u00d7\u200910\n                    <jats:sup>6<\/jats:sup>\n                    \/kg with Cyclo\u2010G (+\/\u2212P);\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.00001). On demand Plerixafor use resulted in &gt;\u200995% successful mobilization in MM and NHL. CD34+ yields are higher using Cyclo\u2010G and Chemo+G in NHL. In MM, G\u2010CSF only resulted in yields sufficient for at least one transplant. In HL, our data show no evidence to support the use of Cyclo\u2010G over G\u2010CSF only.\n                  <\/jats:p>","DOI":"10.1002\/jca.70012","type":"journal-article","created":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T01:39:33Z","timestamp":1741743573000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["G\u2010\n                    <scp>CSF<\/scp>\n                    Only Versus Chemotherapy and G\u2010\n                    <scp>CSF<\/scp>\n                    Peripheral Blood Stem Cell Mobilization for Autologous Hematopoietic Stem Cell Transplant\u2014Assessing a Change in Regime due to the\n                    <scp>COVID<\/scp>\n                    \u201019 Pandemic"],"prefix":"10.1002","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0478-508X","authenticated-orcid":false,"given":"Julia S.","family":"Wolf","sequence":"first","affiliation":[{"name":"Bristol Haematology and Oncology Centre  Bristol UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances","family":"Seymour","sequence":"additional","affiliation":[{"name":"St James University Hospital, LTHT  Leeds UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Parrish","sequence":"additional","affiliation":[{"name":"St James University Hospital, LTHT  Leeds UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thea","family":"Chandler","sequence":"additional","affiliation":[{"name":"St James University Hospital, LTHT  Leeds UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Holt","sequence":"additional","affiliation":[{"name":"St James University Hospital, LTHT  Leeds UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Griffin","sequence":"additional","affiliation":[{"name":"Bristol Haematology and Oncology Centre  Bristol UK"},{"name":"NHS Blood and Transplant  Bristol UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Karakantza","sequence":"additional","affiliation":[{"name":"St James University Hospital, LTHT  Leeds UK"},{"name":"NHS Blood and Transplant  Barnsley UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,3,2]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409\u2010021\u201001227\u20108"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13287\u2010021\u201002379\u20106"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.702"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2013.80"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13287\u2010022\u201002802\u20106"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2004.02.001"},{"key":"e_1_2_10_8_1","unstructured":"NHS England Clinical Reference Group for Blood and Marrow Transplantation \u201cClinical Commissioning Policy: Use of Plerixafor for Stem Cell Mobilisation (Update) \u201d 2015 https:\/\/www.england.nhs.uk\/wp\u2010content\/uploads\/2018\/07\/Plerixafor\u2010for\u2010stem\u2010cell\u2010mobilisation.pdf."},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1700867"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409\u2010018\u20100152\u20102"},{"key":"e_1_2_10_11_1","unstructured":"BSBMTCT COVID\u201019 Vaccination Sub\u2010Group \u201cBSBMT&CT Recommendations for the Management of Adult Patients and Allogeneic Donors During the COVID\u201019 (Causative Agent the SARS\u2010CoV\u20102 Virus) Outbreak [Internet] Version 5; 4th December 2020 (Clinical Guideline) \u201dhttps:\/\/bsbmtct.org\/wp\u2010content\/uploads\/2020\/12\/BSBMTCT\u2010COVID\u201019\u2010Guidelines\u20105.0\u2010Dec\u20102020_final.pdf."},{"key":"e_1_2_10_12_1","unstructured":"UK Myeloma Forum \u201cUK Myeloma Forum Guidance to Support Medical Decision\u2010Making in the Management of Myeloma Patients During the COVID\u201019 (Coronavirus) Outbreak \u201d 2020 https:\/\/b\u2010s\u2010h.org.uk\/media\/18178\/covid_19_ukmf_guidance_document_final_24th_march_2020.pdf."},{"key":"e_1_2_10_13_1","volume-title":"Email to: Marina Karakantza","author":"Griffin J.","year":"2024"},{"key":"e_1_2_10_14_1","unstructured":"Terumo Blood and Cell Technologies \u201cSpectra Optia Apheresis System\u2014Operators Manual \u201d 2018 https:\/\/www.terumobct.com\/spectra\u2010optia."},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2013.10.013"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2010.11.021"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1053\/bbmt.1998.v4.pm9763111"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404801"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520\u2010013\u20101808\u20105"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.131"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2009.02.011"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2405035"},{"key":"e_1_2_10_23_1","unstructured":"National Institute of Health and Care Excellence \u201cMyeloma: Diagnosis and Management. NICE Guideline (NG35) \u201d 2018 https:\/\/www.nice.org.uk\/guidance\/ng35\/chapter\/Recommendations#managing\u2010newly\u2010diagnosed\u2010myeloma."},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352\u20103026(20)30356\u20102"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102009\u201004\u2010205013"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2012.60"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2010.118"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2012.01.005"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.283452"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2020.12.009"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.10.2509"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032290"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V130.Suppl_1.401.401"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.8506"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.07.004"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.11.014"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.0002"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26590"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(14)70245"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352\u20103026(24)00249\u20107"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25664"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000545"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703912"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703364"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704798"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.1999.0915"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2021.103251"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-031-44080-9_16"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2015.09.002"},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2015.322"},{"key":"e_1_2_10_51_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.261842"},{"key":"e_1_2_10_52_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2011.82"},{"key":"e_1_2_10_53_1","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S307520"}],"container-title":["Journal of Clinical Apheresis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jca.70012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T04:55:38Z","timestamp":1749185738000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jca.70012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,2]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1002\/jca.70012"],"URL":"https:\/\/doi.org\/10.1002\/jca.70012","archive":["Portico"],"relation":{},"ISSN":["0733-2459","1098-1101"],"issn-type":[{"value":"0733-2459","type":"print"},{"value":"1098-1101","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,2]]},"assertion":[{"value":"2024-09-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70012"}}